FDA Approved: VITRAKVI — Supplemental Application (Loxo Oncology, Inc.)

View source ↗

Summary

FDA supplemental approval expands VITRAKVI's label to include treatment of NTRK gene fusion-positive solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion-positive Solid Tumors

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

SUPPL AP for VITRAKVI (LAROTRECTINIB)